Floatz logo

CIFURTILIMAB

Lymphoma, B-Cell

Seagen Inc.monoclonal_antibodyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

317 Active assets in the Lymphoma, B-Cell cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

CIFURTILIMAB is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
59 / 100
View asset →
melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
Hodgkins lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →